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Abstract 
Clinical experiences often document, that a successful tumor control requires high doses of 
drug applications. It is widely believed that unavoidable adverse reactions could be minimized 
by using gene-therapeutic strategies protecting the tumor-surrounding healthy tissue as well 
as the bone-marrow. One new approach in this direction is the use of “Targeted Therapies” 
r e a l i z i n g   a   s e l e c t i v e   d r u g   t a r g e t i n g   t o   g a i n   e f f e c t u a l   a m o u n t s   a t   t h e   t a r g e t   s i t e ,   e v e n   w i t h  
drastically reduced application doses. MCF-7 breast cancer cells expressing the αvβ3 [al-
p h a ( v ) b e t a ( 3 ) ]   i n t e g r i n   r e c e p t o r   a r e   c o n s i d e r e d   a s   a p p r o p r i a t e   c a n d i d a t e s   f o r   s u c h   a   t a r g e t e d  
therapy. The modularly composed BioShuttle carrier consisting of different units designed to 
facilitate the passage across the cell membranes and for subcellular addressing of diagnostic 
and/or therapeutic molecules could be considered as an eligible delivery platform. Here we 
used the cyclic RGD-B i o S h u t t l e   a s   a   c a r r i e r   f o r   t e m o z o l o m i d e   ( T M Z )   a t   t h e   αvβ3 integrin 
receptor realizing local TMZ concentrations sufficient for cell killing. The IC50 values are 12 
µMol/L in the case of cRGD-BioShuttle-TMZ and 100 µMol/L for underivatized TMZ, which 
confirms the advantage of TMZ reformulation to realize local concentrations sufficient for cell 
killing. 
Our paper focuses on the design, synthesis and application of the cRGD-BioShuttle conjugate 
composed of the cyclic RGD, a αvβ3 integrin-ligand, ligated to the cytotoxic drug TMZ. The 
ligation was carried out by the Diels Alder Reaction with inverse electron demand (DARinv). 
Key  words:  Click-Chemistry,  Cycloaddition,  BioShuttle,  Ligation  chemistry,  Linker  Systems, 
Adaptor Systems, inverse Diels Alder Reaction, RGD, Tetrazines, targeted Therapy, Temozolomide 
Introduction 
B r e a s t   c a n c e r   i s   o n e   o f   t h e   m o s t   c o m m o n   m a l i g-
nancies  affecting  women  in  developed  countries.[1] 
A p p r o x i m a t e l y   t h r e e   o u t   o f   f o u r   w o m e n   w i t h   b r e a s t  
c a n c e r   d e v e l o p   m e t a s t a s e s   i n   b o n e   w h i c h ,   i n   t u r n ,  
diminish the quality of life.[2] An optimal treatment 
concept for patients needs different therapy modali-
ties and methods with an optimum in efficiency and 




laid on an individual and not just standardized plan 
of treatment for every single patient and all available 
therapy options should be used, such as immunothe-
rapy, surgery or chemotherapy  sensibly  using  cytos-
tatic active agents with acceptable adverse reactions. 
I t   i s   r e m a r k a b l e   h o w   d a t e d   m e d i c a l   t r e a t m e n t   m e-
thods are persistently continued [reported during the 
“International Brain Tumor Research Conference 2010 
(http://www.kgu.de/index.php?id=4290)]. 
T o x i c   s i d e   e f f e c t s   a r e   d o c u m e n t e d   f o r   T M Z   a s  
adverse reactions in the bone-marrow. Moreover, it is 
known from clinical experience, that even higher ap-
p l i c a t i o n   d o s e s   a r e   n e c e s s a r y   f o r   s u c c e s s f u l   t u m o r  
control. This approach seems obsolete now,  because 
’ T a r g e t e d   T h e r a p y ’   h a s   r e a c h e d   t h e   f o c u s   o f   s c i e n t i f i c  
interest in order to minimize such unavoidable drastic 
side  effects.  Strategies  were  discussed  during  the 
aforementioned meeting to protect the bone-marrow, 
e.g.  with  gene-therapeutic  methods.  Another  inter-
esting  field  is  the  regional  chemotherapy  in  which 
cytostatic drugs are being locally applied to certain 
body  regions.  The  topical  application  increases  the 
a m o u n t   o f   a c t i v e   s u b s t a n c e s   i n   t h e   t u m o r   a n d   i m-
proves efficiency, while lowering the side effect rate at 
the same time.  
However, many cell immanent obstacles inhibit 
c h e m i c a l   t h e r a p y ,   s u c h   a s   t h e   m u l t i d r u g   r e s i s t a n c e  
(MDR)  mediated  against  cytotoxic  agents  like  TMZ, 
and apoptosis resistance with disruption of the com-
plex  programmed  cell  death  pathway  network.  The 
Janicke group documented apoptosis resistant MCF-7 
breast  cancer  cells  treated  with  ionizing  radiation, 
however especially breast micro-metastases are diffi-
cult to determine and even more difficult to treat ef-
fectively. 
Therefore only a selective targeting of the drug 
c a n   d e l i v e r   a n   e f f e c t u a l   a m o u n t   o f   T M Z   t o   i t s   t a r g e t  
site, even with drastically reduced application doses. 
H o w   t o   p e r f o r m   t h i s   i s   e x e m p l a r i l y   s h o w n   h e r e   b y  
targeting and controlling breast cancer cells. 
Our  considerations  to  overcome  these  resis-
tance-i n d u c i n g   f a c t o r s   l e d   t o   t h e   a p p l i c a t i o n   o f   l i-
gands, which are target-specific  for  cell-typical sur-
face receptors, as described as follows. 
On these cells the αvβ3 [alpha(v)beta(3)] and αvβ5 
[alpha(v)beta(5)]integrins are heterodimeric cell sur-
face receptors which mediate adhesion between cells 
and the extracellular matrix.[3] The αvβ3 receptor has 
previously  been  implicated  in  a  key  role  of  tumor 
progression,  metastasis  and  osteoclast  bone  resorp-
tion.  [4]  Integrins,  the  corresponding  ligands,  are 
evolutionarily old and have critical roles during de-
velopmental and pathological processes. The antibo-
dies  to  αvβ3  integrin  and  its  antagonists  like 
arg-gly-asp  (RGD)-containing  peptides,  including 
osteopontin, bone sialoprotein, vitronectin and fibri-
nogen are considered as efficient inhibitors which can 
control the tumor progression.[5] 
This αvβ3 integrin receptor is documented as an 
outstanding target in the field of tumor imaging [6-8] 
and is equally important as a chemotherapeutic target 
in the field of targeted therapy.[9] 
Endocytosis-mediated intracellular trafficking of 
ligands via the αvβ3 receptor of MCF-7 cells and the 
αvβ5 integrin receptor into the perinuclear region of 
HeLa cells is documented, which lack the functional 
αvβ3  receptor.[10]  Interestingely  HeLa  cells,  which 
express the αvβ3 integrin receptor at low level, possess 
lower invasive potential than MCF-7   c e l l s .   I n   o u r   e x-
periments we used MCF-7   h u m a n   b r e a s t   c a n c e r   c e l l s  
a n d   H e L a   c e r v i x   c a n c e r   c e l l s   t o   i n v e s t i g a t e   t h e   n e w  
cRGD-BioShuttle as a delivery platform for targeting 
w i t h   T M Z   i n   o r d e r   t o   r e a l i z e   h i g h   l o c a l   T M Z   c o n c e n-
trations  at  the  MCF-7 and HeLa cell’s surfaces and, 
after uptake into the cells sufficient for cell killing.  
T h i s   p a p e r   i n t e n d s   t o   s u m m a r i z e   t h e   m a j o r   e f-
forts  reached  thus  far  and  focuses  on  the  design, 
synthesis  and  application  of  the 
cRGD-BioShuttle-T M Z   c o n j u g a t e .   T h e   w h o l e   m o l e-
cule was synthesized via Diels Alder Reaction with 
i n v e r s e   e l e c t r o n   d e m a n d .   I t   i s   c o m p o s e d   o f   t h e   c y c l i c  
RGD-containing the αvβ3 and αvβ5 integrin antagonist 
cRGD.  
Cell culture 
The  estrogen  sensitive  MCF-7  adenocarcinoma 
breast cancer and HeLa cervix cancer cells (dkfz, tu-
morbank)  were maintained at 37°C in a 5% CO2 at-
mosphere  in  RPMI  cell  medium  (Gibco,  Germany) 
supplemented  with  5%  fetal  calf  serum  (Biochrome, 
Germany). The cells were split twice a week.  
Chemical Procedures 
Synthesis of the RGD-BioShuttle 




ne-3-yl)benzoic  acid  (3)  was  prepared  from 
2-cyanopyrimidine  1 and  4-cyano-benzoic  acid  2 by 
reaction with hydrazine and then oxidized with so-
dium nitrite to the tetrazine derivative 4 according to 
the following procedure [11]. The tetrazine derivative 
was converted with thionyl chloride under standard 
conditions to the chloride 5.   T o   t h i s   s u s p e n s i o n   o f   t h e  




N-Boc-1,3-diaminopropane  (2  mmol)  and  TEA  (2 
mmol)  in  10  ml  CH2Cl 2 was slowly added at 0-5°C. 
The  resulting  solution  was  deeply  coloured  and 
maintained  for  4  h  at  room  temperature.  Then  the 
organic phase was w a s h e d   w i t h   w a t e r ,   f o l l o w e d   b y  
1N HCl and again water. The organic layer was dried 
over  Na2SO4  and  evaporated.  The  resulting  residue 
w a s   c h r o m a t o g r a p h e d   o n   s i l i c a   g e l   b y   e l u t i o n   w i t h  
chloroform/ethanol (9:1) and further purified by re-
crystallization  from  ac e t o n e .   Y i e l d :   5 0   t o   7 0   %   d e-
p e n d i n g   o n   t h e   q u a l i t y   o f   t h e   c a r b o x y l i c   a c i d .   E S I   M S :  
m/z  437.2  [M]+.   T h e   B o c -protected  derivative  was 
t r e a t e d   w i t h   T F A   ( 5   m l )   f o r   3 0   m i n   a t   r o o m   t e m p e r a-
t u r e   a n d   i s o l a t e d   b y   e v a p o r a t i o n   t o   a   s o l i d   r e s i d u e   ( 6) 




Figure A  shows  the  mass  of  the 
N-(2-Aminopropyl)-4-(6-(pyrimidine-2-yl)-1,2,4,5-tetrazine





oxylic acid chloride 7 
3-Methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,
5]tetrazine-8-c a r b o x y l i c   a c i d   w a s   c o n v e r t e d   t o   t h e  
corresponding  chloride  7  as  documented  by  Ar-
rowsmith [13].   T h e   a c i d   ( 2   m m o l )   w a s   r e f l u x e d   w i t h  
thionyl chloride (10 ml) until the acid was completely 
d i s s o l v e d .   T h e   e x c e s s   o f   t h i o n y l   c h l o r i d e   w a s   e v a p o-
rated  under  vacuum   a n d   t h e   r e s u l t i n g   s o l i d   w a s  
stored over NaOH. 
3-Methyl-4-oxo-N-(3-(4-(6-(pyrimidine-2-yl)-1,2,4,5-tetrazine-3-yl)
benzamido)propyl)-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine- 
8-carboxamide (TMZ-tetrazine diene) 9 
Compound 8 (0.5 mmol) and the chloride 7 (0.5 
mmol) were dissolved in 5 ml chloroform and 5 ml 
T E A   a t   0 -5   ° C .   A f t e r   4   h   a t   r o o m   t e m p e r a t u r e ,   t h e   s o-
lution was washed with water, 1 N HCl and again 
with water. The organic layer was dried over Na2SO4 
and evaporated. The r e s i d u e   w a s   p u r i f i e d   b y   c h r o-
matography  (silica  gel)  with  chloroform/ethanol 






Figure B  shows  the  mass  of 
3-methyl-4-oxo-N-(3-(4-(6-(pyrimidine-2-yl)-1,2,4,5-tetrazi
ne-3-yl)benzamido)propyl)-3,4-dihydroimidazo[5,1-d][1,2,3
,5]tetrazine-8-carboxamide  {TMZ-tetrazine  diene  (9  in 




Derivatizations of the cRGD 
Synthesis of the Reppe anhydride 12 
The  tetracyclo-[5.4.21,7.02,6.08,11]3,5-dioxo-4-aza- 
9,12-tridecadiene (Reppe-anhydride) 12 was prepared 
f r o m   4 2   m g   o f   ( 1 Z , 3 Z , 5 Z , 7 Z ) -cycloocta-1,3,5,7-tetraene 
10 and 44 mg maleic anhydride 11 in chloroform as 
documented by Reppe [14].  





Figure S1 (Scheme 1)  the  nitriles  1  and  2  react  with  hydrazine  to  the  4-(6-(pyrimidine-2-yl)-1,4-dihydro- 
1,2,4,5-tetrazine-3-yl)benzoic acid 3. Oxidation to 4 and reaction with thionyl chloride result in the corresponding acide 
c h l o r i d e   5   w h i c h   r e a c t s   w i t h   N-Boc-1,3-diaminopropane to the product 6. Boc-deprotection and subsequent reaction with 
3-Methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylic  acid  chloride  7  result  in  the  product 
3-Methyl-4-oxo-N-(3-(4-(6-(pyrimidine-2-yl)-1,2,4,5-tetrazin-3-yl)benzamido)propyl)-3,4-dihydroimidazo[5,1-d][1,2,3,5]tet
razine-8-carboxamide (TMZ-tetrazine diene) 9. 
 
Figure S2 (Scheme 2) illustrates the chemical reaction of (1Z,3Z,5Z,7Z)-cycloocta-1,3,5,7-tetraene 10 and 44 mg maleic 
anhydride 11 which produces the tetracyclo-[5.4.2
1,7.0
2,6.0
8,11]-3,5-dioxo-4-aza-9,12-tridecadiene 14 (NMH data of 12 are 








Figure C  shows  the 
1H-NMR-spectrum  of  the  Reppe 




3,5-dioxo-4-aza-9,12-tridecadiene in CDCl3}. The structure 
describes the shift calculation for protons of the compound 
with ChemDraw Ultra 2004. (Numbers indicate the pre-
dicted shift of the signals in ppm, as discussed by Wiessler 
[12].  
Synthesis of the dienophile cRGD-Lys(Tct) (14) 
3 0   µ m o l   c R G D   p e p t i d e   ( 1 8   m g )   13 and 40 µm o l   ( 8  
mg)  tetracyclo-[5.4.21,7.02,6.08,11]3,5-dioxo-4-aza-9,12- 
tridecadiene  12  were  dissolved  in  pyridine  over  5 
hours at 70° - 80°C. Yield: 6 mg 14. Empirical formula 
C39H49N9O9; exact Mass: 787.37 Mol. Wt.: 787.86 
m/e:  787,37  (100,0%),  788,37  (43,1%),  789,37 
(12,3%), 788,36 (3,3%), 790,38 (1,2%), 790,37 (1,1%) C, 
59.45; H, 6.27; N, 16.00; O, 18.28 m/e peak at 788.5 for 
the product. 
L i g a t i o n   o f   t h e   c R G D -L y s ( T c t )   w i t h   t h e   T M Z -tetrazine 9 
Equimolar  amounts  of  the  TMZ-tetrazine  con-
jugate 9 (1.03 mg; 2 µmol) and cRGD-Lys(Tct) 14 (7.3 
mg, 2 µmol) were dissolved in aqueous solution and 
s t o r e d   a t   r o o m   t e m p e r a t u r e   f o r   2 4   h .   T h e   D A R inv re-
action occurs at room temperature and was completed 
a f t e r   t h e   c o l o u r   c h a n g e d   f r o m   m agenta to yellow. The 
product  15 (cRGD-BioShuttle-TMZ)   w a s   i s o l a t e d   b y  
lyophilization; yield: 98 %); MS ESI: m/e 1634.8; cal-
culated C81H91N19O15S2 1633.6. 
 
 
Figure S3 (Scheme 3) shows the DARinv reaction of the diaryl-tetrazine harbouring TMZ 9 with cRGD functionalized with 





Synthesis of the cRGD-dansyl 
For investigations of the cellular localization of 
t h e   c R G D   w e   f u n c t i o n a l i z e d   t h e   c R G D   w i t h   t h e   f l u o-
rescent  dye  5-(dimethylamino)-naphthalene-1- 
sulfonyl, (dansyl, as shown in scheme 4/Figure S4).  
 
Figure S4 (Scheme 4) shows  the  DARinv  reaction  of  the  diaryl-tetrazine  harbouring  the  5-(dimethylamino)- 
naphthalene-1-sulfonyl  dye  16  with  cRGD  functionalized  with  the  Reppe  Anhydride  14  to  the  product  17 
(cRGD-BioShuttle-dansyl). 
 
Synthesis of the cRGD-dansyl 17 
2   µ m o l   ( 1 . 7 5   m g )   o f   p u r i f i e d   14 reacts over 24 
hours with 2.5 µmol (2.18 mg) 16 dissolved in DMSO 
a t   r o o m   t e m p e r a t u r e   t o   t h e   p r o d u c t   17. The reaction 
mixture  was  concentrated.  After  HPLC  purification 
t h e   e s t i m a t i o n s   o f   i d e n t i t y   s h o w   i n   p o s i t i o n   1 6 3 4 ,  
Mode m/e. 
Exact Mass: 1633.64; Mol. Wt.: 1634.84 
m/e:  1633.64  (100.0%),  1634.64  (97.8%),  1635.65 
(39.3%),  1636.65  (14,2%),  1636.64  (11.9%),  1635.64 
(10.8%), 1635.63 (9.4%), 1637.65 (4,7%), 1637.64 (4,2%), 
1638.64 (1.6%) 
C, 59.51; H, 5.61; N, 16.28; O, 14.68; S, 3.92 
Chemotherapy treatment of MCF-7 breast can-
cer and HeLa cervix cancer cells 
Pure  temozolomide  (TMZ)  [Sigma-Aldrich, 
G e r m a n y   ( C a t .   N o .   7 6 8 9 9 ) ]   w a s   s u b d i v i d e d   i n t o   two 
p a r t s   f o r   s u b s e q u e n t   p r o c e s s i n g .   O n e   p a r t   w a s   k e p t  
underivatized  for  the  following  experiment and the 
second part, after chemical transformation to the cor-
responding acid chloride 7,   w a s   u s e d   f o r   c o u p l i n g   t o  
the  cRGD  [Peptides  International,  USA  (Cat.  No. 
PCI-3661-PI)] transporter molecule.  
TMZ  and  cRGD-BioShuttle-TMZ  15  were  both 
dissolved  in  10  %  aqueous  solution  of  acetonitrile 
(Sigma-A l d r i c h ,   G e r m a n y ) .   C o n t r o l   s t u d i e s   w i t h   a c e-
tonitrile  were  performed  to  exclude  potential  toxic 
effects of this solvent.  
MCF-7   a n d   H e L a   c e l l s   w e r e   g r o w n   a s   s u b c o n-
f l u e n t   m o n o l a y e r s   i n   R P M I   (control)  and  in  RPMI 
containing  appropriate  amounts  of  TMZ  and  the 
cRGD-BioShuttle-TMZ  15  ( 5 0   µ M )   a n d   t h e i r   b e h a v-
iour was analyzed for up to 72 hours.  
Morphological evaluation 
Microscopical studies of the human cancer cells 
w e r e   c a r r i e d   o u t   w i t h   a n   Olympus inverted micro-
scope under phase contrast conditions. The magnifi-
c a t i o n   w a s   2 0 0 f o l d .   T h e   c e l l s   w e r e   o b s e r v e d   d u r i n g  
their culture in medium and during  treatment  with 




Cellular localization of the 
cRGD-BioShuttle-dansyl 
In order to reconfirm our data documenting an 
endocytotic  internalization  of  the  cRGD  into  the  cy-
toplasm of αvβ3 and αvβ5 integrin expressing cells we 
used the confocal laser scanning microscope (CLSM) 
of the Microscopy Core Facility of the German Cancer 
Research Cen t e r   f o r   q u a l i f i e d   v e r i f i c a t i o n   o f   t h e   d a t a .  
T h e   p i c t u r e s   w e r e   t a k e n   w i t h   a   L e i c a   c o n f o c a l   m i c r o-
s c o p e   T C S   S P 5   I I   ( e x c i t a t i o n   a t   4 0 5   n m ,   e m i s s i o n   a t  
420-5 6 0   n m )   a n d   e x a m i n e d   w i t h   t h e   L e i c a  
LAS-Software.  
24 hours before CLSM measurements both cell 
lines, the HeLa and the MCF-7 cells (5×105), were cul-
tivated  in  8-well  cell  culture  plates  (Lab-Tek)  and 
treated  with  the  cRGD-BioShuttle-dansyl  (12.5  µM) 
17.  
Cytotoxic Measurements 
For  the  toxicological  characterization  of  the 
cRGD-BioShuttle-TMZ  conjugate  15  as  well  as  the 
c R G D   a n d   t h e   T M Z   a l o n e  as controls were added to 
the  MCF-7 cell line’s medium. The substances  were 
incubated in a dilution series ranging from 12.5, via 
25, 50, to 100 µM final concentrations up to 72 hours. 
The IC50 values were determined and also converted 
to the pIC50 scale (-log IC50) (Table 1).  
Multiparametric Flow Cytometry Analysis 
Cell size and granularity 
T h e   u s e   o f   t h e   f l o w   c y t o m e t r y   p a r a m e t e r s   f o r-
ward (FSC) and sideward (SSC) scatter of the cells 
give an indication on drug effects through the relative 
cell  size  and  structural  effects  such  as  granularity. 
Both parameters suffice for a rough cell characteriza-
tion.  The  cells  (treated  with  the  components  as  de-
scribed  above  and  an  untreated  control)  could  be 
clearly distinguished as shown in the Figure 5.  
 
Results 
This manuscript details the synthetic steps of our 
n e w   c R G D -BioShuttle-T M Z   a n d   illustrates the cellular 
uptake  of  this  newly  synthesized 
cRGD-BioShuttle-TMZ  in  comparison  to  its  controls 
as outlined in the respective experiments. We exam-
ined MCF-7   a n d   H e L a   c e l l s   s u r f a c e   t a r g e t i n g   o f   t h e s e  
molecules with the cytotoxic drug TMZ as a cargo.  
Light Microscopical Studies 
I n   l i g h t   m i c r o s c o p y   w e   f i r s t   i n v e s t i g a t e d   t h e   c e l l  
killing effect of cRGD-Bioshuttle-TMZ 15 compared to 
underivatized TMZ. We achieved a rapid and high 
local concentration and an accumulation of TMZ on 
the  surface  of  the  targeted  αvβ3  integrin expressing 
MCF-7   c e l l s   b y   u s e   o f   t h e   c R G D -BioShuttle as delivery 
and targeting platform.  
Figure 1 r e v e a l s   t h e   d i f f e r e n t   e f f e c t s   o f   T M Z   a n d  
cRGD-BioShuttle-TMZ on MCF-7 cells tested after 24 
hours and 72 hours of treatment with a final concen-
tration of 50 µM. Whereas the MCF-7 cells exhibit no 
formation of the squamous epithelium (B), the MCF-7 
cells  seem  to  be  unimpressed  by  TMZ  treatment 
(bottom  row  C) and resemble the untreated control 
(top row A) as shown in the microscopic pictures. 
Figure  2  indicates a clear change of the MCF-7 
phenotype  dependent  on  the  concentrations  of 
cRGD-BioShuttle-T M Z   o f   u p   t o   5 0   µ M .   T h e   u n t r e a t e d  
c o n t r o l   c e l l s   a r e   s h o w n   i n   t h e   b o t t o m   r o w   f o r   e a c h  
treatment  regimen.  The  final  concentrations  of  the 
cRGD-BioShuttle-T M Z   a n d   T M Z   w e r e   f r o m   1 2 . 5   µ M ,  
v i a   2 5   µ M   t o   5 0   µ M   a s   i n d i c a t e d   i n   t h e   f i g u r e   2 .   A  
drastic cell killing of the MCF-7   c e l l s   w a s   o b s e r v e d   b y  
the  targeted  approach,  whereas  the  MCF-7  cells 
treated with underivatized temozolomide seemed to 
be  not  affected.  Independent  of  the  final  TMZ  con-
centrations  used,  they  looked  identical  to  the  un-
treated control cells. 
Cellular Localization Studies using Confocal La-
ser Scanning Microscopy – CLSM 
I n   o r d e r   t o   i n v e s t i g a t e   t h e   o p e n   q u e s t i o n   o f   t h e  
cellular localization of the cRGD-BioShuttle-TMZ  we 
ligated a   f l u o r e s c e n c e   d y e   t o   c R G D .   T h i s   “ B i o S h u t t l e ”  
( c y c l o   R G D )   c o n n e c t e d   t o   a   f l u o r e s c e n t   t a g   d a n s y l   ( a s  
shown  in  scheme  4/Figure  S4)   w a s   a p p l i e d   t o   t h e  
c u l t u r e   m e d i a   o f   t h e   αvβ3 and αvβ5 integrin expressing 
MCF-7 and the low ex p r e s s i n g   H e L a   c e l l s .   T h e   c e l l s  
lines clearly show differences in the fluorescence sig-
nal  localizations.  Two  hours  after 
cRGD-BioShuttle-dansyl  application  a  blue  perinu-
clear dansyl fluorescence signal could be observed in 
MCF-7 .   T h e   c e l l   n u c l e u s   d i s p l a y e d   n o   s i g n a l   a t   a l l . The 
HeLa cells show a cells surface located fluorescence 
signal (Figure 3, top row).  
24 hours after cRGD-BioShuttle-dansyl  applica-
tion the fluorescence signal increased in the cytoplasm 
of  MCF-7 and at the surface of HeLa cells,  but  the 
signal  localizations  remained  unaltered.  A  nuclear 
located fluorescence signal was still lacking (as shown 
in Figure 3, second row). The pictures from 48 and 72 
hours after application demonstrate a decreased flu-
orescence signal suggesting  a n   e f f l u x   o f   t h e   d a n s y l  
fluorescence dye out of the MCF-7 cell’s cytoplasm, 
whereas  in  contrast  the  fluorescence  signal  at  the 
HeLa cell’s surface is unchanged (Figure 3, row 3 and 




Cellular localization of the dansyl fluorochrome 
For detailed information about the cellular loca-
l i z a t i o n   o f   t h e   d a n s y l   f l u o r o c h r o m e   8   p i c t u r e s   o f   a  
z-s t a c k   w e r e   v i s u a l i z e d   i n   l a y e r s   b y   C L S M .   I t   i s   d e-
monstrative, that some fluorescence signals are shown 
i n s i d e   o f   t h e   c e l l s ,   b u t   t h e   s i g n a l   i s   not only localized 
at  the  cell’s  surface  but  also  detectable  inside  as 
pointed out in the legend of the figure 4.  
Multiparametric FACS analysis 
T h e   m o r p h o l o g i c a l   p a r a m e t e r s   o f   t h e   F A C S  
a n a l y s i s   s h o w s   a n   u n a l t e r e d   c e l l   s i z e   ( F i g u r e   5 ,  bottom 
row), whereas the granularity (influenc e d   b y   s i z e   a n d  
s t r u c t u r e   o f   t h e   c e l l   n u c l e u s   a n d   b y   t h e   q u a n t i t y   o f  
vesicles) is changed and shows an increased fraction 
o f   m o r e   g r a n u l i z e d   M C F -7  cells  in  all  treatments 
( T M Z ,   c R G D ,   a n d   cRGD-BioShuttle-TMZ) in contrast 
t o   t h e   u n t r e a t e d   M C F -7   c o n t r o l   c e l l s .   A s   d e m o n s t r a t e d  
in figure 5 the granularity of MCF-7 cells is increased 
i n   c e l l s   t r e a t e d   w i t h   T M Z   a n d   c R G D   ( 1 0 0   µ M   r e s p e c-
t i v e l y ) .   T h e   m o s t   c o n s p i c u o u s   g r a n u l a r i t y   w a s   o b-
tained  after  cRGD-BioShuttle-T M Z   i n   t h e   f i n a l   c o n-
c e n t r a t i o n   o f   1 2 . 5   µ M   a s   s h o w n   i n   t h e   b l o t   o f   t h e  figure 
5 (right column, row 1). 
T h e   t r e a t m e n t   o f   T M Z ,   c R G D ,   a n d  
cRGD-BioShuttle-TMZ in the concentrations as men-
tioned  above  shows  no  visible  influence  on  the  cell 
size of MCF-7 cells. 
 
Figure 1  shows m i c r o s c o p i c a l   D I C   s t u d i e s   o f   h u m a n   b r e a s t   c a n c e r   c e l l s   ( M C F -7 ) .   T h e   t o p   r o w   ( A) shows the phenotype 
o f   u n t r e a t e d   M C F -7   c e l l s .   T h e   c e n t e r   r o w   ( B) exhibits MCF-7   c e l l s   a f t e r   2 4   h o u r s   ( l e f t   c o l u m n )   a n d   7 2   h o u r s   ( r i g h t   c o l u m n )  
of treatment with the cRGD-BioShuttle-T M Z   1 5   t a r g e t e d   t o   t h e   M C F -7 cells surface arranged αvβ3 and αvβ5 integrins. 
MCF-7   c e l l s   t r e a t e d   w i t h   T M Z   a l o n e   a r e   s h o w n   i n   t h e   b o t t o m   r o w   ( C) .   T h e   f i n a l   c o n c e n t r a t i o n s   o f   t h e   t e s t e d   T M Z   a n d  





Figure 2  illustrates the concentration dependent change of the phenotype of MCF-7 cells 72 hours after treatment with 
TMZ alone and cRGD-BioShuttle-TMZ. The left column represents the TMZ treatment; the untreated controls are at the 
lower end. The columns on the right side show treatment with the cRGD-BioShuttle-TMZ beginning with 50 µM via 25 µM 
to 12.5 µM. 






Figure 3  The  figure  shows 
CLSM pictures of breast cancer 
cells MCF-7 (right column) and 
cervix  cancer  cells  HeLa  (left 
column). The lines of the figure 
indicate the measurement time 
points from 2h, 24h, 48h, up to 
72h and suggest a different cel-
lular  localization  of  the 
cRGD-BioShuttle-dansyl  mole-
cule  in  both  investigated  cell 
lines.  Two  hours  after 
cRGD-BioShuttle-dansyl  appli-
cation the molecule seems to be 
arrested on the surface of HeLa 
cells,  whereas  the  dan-
syl-fluorescence  can  be  ob-
served  in  the  cytoplasm  of 
MCF-7 cells. 24 hours later and 
up to 72 hours, the localization 
of  the  fluorescence  signal  was 
unaltered on th e   s u r face of HeLa 
cells. The MCF-7   c e l l s   s h o w   a  
clear fluorescence signal in the 
cytoplasm  except  from  cell 
nuclei which present no signal. 
From  48  to  72  hours  after 
cRGD-BioShuttle-dansyl  appli-
cation the fluorescence signal in 
the  MCF-7’s  cytoplasm  dimi-
nishes  increasingly.  The  final 
concentration  of  the 
cRGD-BioShuttle-dansyl was 50 





Figure 4  The gallery represents 8 CLSM pictures of treated HeLa cells in the x, y, and in the z-direction showing layers 
across HeLa cells. The pictures are taken from top to the bottom in a 2 µM distance. In these HeLa cells we were able to 





Figure 5  the FACS analysis blots illustrate from left to right the effect of control TMZ, cRGD, and cRGD-BioShuttle-TMZ 
on the cell granular i t y   ( t o p   r o w )   a n d   o n   t h e   c e l l   s i z e   ( b o t t o m   r o w )   o f   M C F -7   c e l l s .   A s   s h o w n   i n   t h e   t o p   r o w   o f   t h e   f i g u r e ,   t h e  
granularity differs from the untreated control and increases from the left (via TMZ and cRGD) to the right column 
(cRGD-BioShuttle-T M Z ) ,   w h e r e a s   t h e  cell size remains unaltered (as shown in the bottom row). The highest granularity is 
shown in the MCF-7 cells treated with the cRGD-BioShuttle-T M Z   i n   a n   8 -fold reduced application dose (right column, top 




A   c o m p a r i s o n   o f   t h e   f l o w   c y t o m e t r y   d a t a   ( T a b l e  
1 )   t o   t h e   C L S M   d a t a   a s   s h o w n   i n   F i g u r e   3   r i g h t   c o l-
u m n   i s   u s e f u l .   I n   t h e   i m a g e   o f   t h e   2 4   h o u r s   t i me point 
after  application  with  cRGD-BioShuttle-dansyl  the 
MCF-7  cells  show  a  clear  perinuclear  endoplasmic 
reticular  located  blue  fluorescence  signal  which 
represents  an  increase  in  the  granularity  resulting 
f r o m   t h e   u n s t a i n e d   e n d o p l a s m i c   r e t i c u l u m   s u r-
roun d i n g   t h e   n u c l e u s .   A s   d e m o n s t r a t e d   i n   t h e   F i g u r e  
5 ,   s e c o n d   r o w ,   t h e   c e l l s   t r e a t e d   w i t h   1 0 0   µ M   T M Z  
s h o w   a n   i n c r e a s e d   a m o u n t   o f   g r a n u l a r   c e l l s   ( 2 0   % )  
compared to the untreated control with 4.5% granu-
l a r i t y .   I n   t h e   s a m p l e   o f   M C F -7 cells treated with the 
cRGD alone (100 µM), a cellular granularity of 33.2 % 
w a s   m e a s u r e d .   I t   i s   i m p o r t a n t   t o   n o t e   t h a t   t h e   M C F -7 
cells treated with cRGD-BioShuttle-T M Z   i n   a n   a t   l e a s t  
8-fold reduced application dose (12.5 µM) feature the 
highest  cell  response  with  a  cellular  granularity  of 
34.2%.  
Cellular sensitivity against cRGD, 
cRGD-BioShuttle-TMZ and TMZ alone - IC50 
values 
To  measure  the  chemotherapeutic  sensitivity 
against  the  investigated  components,  the  TMZ,  the 
cRGD, and the cRGD-BioShuttle-TMZ-conjugate were 
added  to  MCF-7  cells.  A g a i n ,   t h e   s u b s t a n c e s   w e r e  
dissolved  in  an  aqueous  dilution  series  in  culture 
m e d i u m   i n   a   c o n c e n t r a t i o n   f r o m   1 2 . 5   µ M   t o   1 0 0   µ M  
and applied over 72 hours. The data are presented in 
Table 1. With the flow cytometry analyses we showed 
the  high  sensitivity  of  MCF-7  against 
cRGD-BioShuttle-TMZ with an IC50 value of 12.5 µM, 
and  a  much  lesser  sensitivity  against  underivatized 
T M Z   w i t h   a n   I C 5 0   o f  1 0 0   µ M ) .   T h e   M C F -7   c e l l s   t r e a t e d  
with cRGD (12.5 up to 100 µM) were unimpressed. 
 
Table 1  Effect of the temozolomide (TMZ), cRGD, and 
cRGD-BioShuttle-TMZ on the MCF-7 breast cancer cell 
line. 
  TMZ  cRGD  cRGD-BioShuttle 
IC50 [µMol/L]  100  -  12.5 




As definitive treatments of metastases of breast 
cancer  remain  surgery,  radiation  therapy,  and  hor-
mone therapy in the case of metastatic progress. Cy-




mosome number between hypertriploidy and hypo-
tetraploidy, could answer the question of the recalci-
t r a n c e   o f   m e t a s t a t i c   b r e a s t   c a n c e r   c e l l s ,   e x e m p larily 
MCF-7 cells, against therapeutic interventions. But the 
t i m i n g   o f   t r e a t m e n t   f o r   a l l   s t a g e s   o f   t h e   d i s e a s e   r e-
mains controversial and new therapeutic approaches 
are needed [15,  16].   E n c o u r a g i n g   r e s u l t s   o f   t h e   c h e-
motherapeutic  T M Z   t r e a t m e n t   i n   b r a i n   t u m o r s   [17] 
remain u n e n d o r s e d   i n   t h e   t r e a t m e n t   o f   b r e a s t   c a n c e r  
cells.  
A  May  28th  2010 search in the NCBI database 
PubMed  with  “RGD”  “MCF-7” yields 26, and with 
“RGD” “HeLa” 89 hits. In its first 1995 publication the 
Huang  group  described  inhibiting  features  of 
RGD-containing  peptides  against  αvβ3  integrin  ex-
pressing cells [18] whereas the activity of αvβ5 integrin 
was  already  documented  from  the  Boulanger  and 
Nemerow groups in 1993 [19, 20].  
An explanation is that the integrin αvβ3 receptor 
is  expressed  at  low  levels  in  epithelial and mature 
end o t h e l i a l   c e l l s   b u t   i s   u p r e g u l a t e d   o n   t u m o r   c e l l s   a n d  
tumor  endothelial  cells   o f   v a r y i n g   t u m o r   t y p e s   i n-
cluding breast cancer, and therefore became consid-
ered as a prognostic factor in breast cancer [21]. It was 
also  documented  that  peptide  ligands  containing 
RGD  amino  acid  sequences   h a v e   a   h i g h  affinity for 
integrins and after labelling with radioisotopes, could 
be used for imaging αvβ3 receptor levels by PET or 
SPECT studies [22]. The use of RGD peptides ligated 
with imaging components for cell specific targeting as 
tumor-diagnosing  tool  is  broadly  documented  [23, 
24].   A l l   t h e s e   d o c u m e n t e d   r a d i o l i g a n d s   m a y   b e   v a l u-
able for monitoring antiangiogenic therapeutics.  The 
ligation  of  such  therapeutically  active  substances  to 
R G D   p e p t i d e s   c o u l d   o p e n   a   d o o r   f o r   s u c c e s s f u l  
treatment of hardly tractable tumors like metastases 
expressing  αvβ3  integrin.  In  comparison  with  the 
normal expression level of MCF-7 mammary cancer 
cells,  αvβ3  l o w   e x p r e s s i n g   H e L a   c e r v i x   c a n c e r   c e l l s  
were examined, which express the αvβ5 integrin  and 
correlate with low invasiveness.  
In flow cytometry, the increased relative amount 
o f   c e l l s   r e v e a l i n g   g r a n u l a r i t y   a n d   t h e   a c c e s s i o n   o f   t h e  
cell  fraction  featuring  a  clear  augmentation  of  the 
granularity both might result from increased numbers 
of  affected  mitochondria,  golgi  apparatus  or  endo-
plasmatic reticulum. This could be explained with  a 
p h a r m a c o l o g i c   e f f e c t   o f   t h e   c R G D ,   a s   w e l l   a s   o f   t h e  
TMZ  alone.  The  BioShuttle  construct  containing  the 
cRGD as targeting modul connected to the TMZ via 
the  Diels-Alder  Reaction  with  inverse  electron  de-
mand  [12]  targets  the  αvβ3  and  αvβ5integrin MCF-7 
cell  surface  proteins  as  shown  in  the  Figure  3.  Ac-
cording to CLSM-pictures of the MCF-7  cells (Figure 
3), an increased cytoplasmic coloring is indicative for 
a strongly increased amount of granularity  in  cells 
( R 2 )   i n   t h e   c y t o m etric results. It is important to note 
that no changes in cell size could be observed.  
The  results  of  the  present  study  demonstrate a 
close relationship of the reformulated drug to unan-
swered clinical questions as suitable solutions for the 
patients  (as  described in the introduction). Here we 
l i g a t e d   T M Z   t o   t h e   c R G D ,   a   p e p t i d e -based  compo-
nent, which accumulates at the cell’s membrane sur-
f a c e   h o l d i n g   a   t r e m e n d o u s   p o t e n t i a l   t o   o p t i m i z e  
therapy. Enhanced local concentrations of active sub-
s t a n c e s   l i k e   T M Z   a t   t he cells surface, a feasible site of 
pharmacological action, allow expecting lower appli-
cation  doses  with  concomitantly  decreased 
side-effects.  The  uptake  and  internalization  into  the 
c e l l s   c y t o p l a s m   i s   p r e s u m a b l y   d o c u m e n t e d   [25].  The 
criteria  to  determine  the  applicability  for  targeting 
including accessibility, specificity, safety and subcel-
lular  precision  are  documented  [26-30].   I n   o r d e r   t o  
fulfill a l l   t h e s e   b i o m e d i c a l   a s p e c t s ,   t h e   T M Z   d r u g   w a s  
bound  as  a  cargo  to  transporter  molecules 
(cRGD-BioShuttle-TMZ)  with  special  chemical 
methods [31].   T h e s e   c o u p l i n g   r e a c t i o n s   h o w e v e r ,   r e-
quired the reformulation of the active drug TMZ and 
c a n   l e a d   t o   n o v e l   p r o p e r t i e s   o f   t h e   T M Z .   C h e m o s e l e c-
tive  reaction-conditions  in  aqueous  solution  and  at 
r o o m   t e m p e r a t u r e   w e r e   o b t a i n e d   b y   c hemical ligation 
o f   f u n c t i o n a l   p e p t i d e s   v i a   t h e   D A R inv.  The  “click 
chemistry” based on the DARinv with “inverse elec-
tron demand” resulted in an impressive efficiency as 
illustrated in scheme 3/Figure S3 and is well docu-
mented [12]. This reaction enhanced the economics of 
the chemical reaction by the following parameters:  
increase of the reaction rate,  gentle reaction condi-
tions at room temperature, and  resulting in reaction 
kinetics with stoichiometric reaction partners without 
excess of the educts. The BioShuttle-mediated deliv-
ery and targeting platform can facilitate the transport 
t o   t a r g e t   c e l l s   [ 3 1 ,   3 2 ] .   D e s p i t e   t h e   f a c t   t h a t   t h e   I C 5 0  
value can vary, depending on factors like the cell line, 
the test protocol, and the investigator, this estimation 
gives useful and helpful information on the relative 
toxicity [32]. Regarding the difference in IC50 values 
between  the  TMZ  at  100  µmol/L  and 
cRGD-BioShuttle-T M Z   a t   1 2 . 5   µ m o l / L ,   i t   b e c o m e s  
obvious that the cRGD-BioShuttle-TMZ offers a high 
potential for treatment of patients and represents an 
attractive enhanced drug system for upcoming clini-
cal combined chemotherapeutic approaches [33, 34].  
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